MetLife Investment Management’s Celldex Therapeutics CLDX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.16M	Sell	36,663 -349	-0.9%	-$9.51K	0.01%	1330
2025 Q4	$1.01M	Sell	37,012 -1,992	-5%	-$52.5K	﹤0.01%	1429
2025 Q3	$1.01M	Hold	39,004	–	–	﹤0.01%	1441
2025 Q2	$794K	Hold	39,004	–	–	﹤0.01%	1439
2025 Q1	$708K	Sell	39,004 -616	-2%	-$13.8K	﹤0.01%	1532
2024 Q4	$1M	Buy	39,620 +2,288	+6%	+$62.2K	0.01%	1413
2024 Q3	$1.27M	Hold	37,332	–	–	0.01%	1257
2024 Q2	$1.38M	Buy	37,332 +5,568	+18%	+$210K	0.01%	1169
2024 Q1	$1.33M	Buy	31,764 +7,691	+32%	+$316K	0.01%	1142
2023 Q4	$955K	Hold	24,073	–	–	0.01%	1319
2023 Q3	$662K	Hold	24,073	–	–	0.01%	1463
2023 Q2	$817K	Buy	24,073 +349	+1%	+$11.8K	0.01%	1382
2023 Q1	$854K	Sell	23,724 -901	-4%	-$38.9K	0.01%	1310
2022 Q4	$1.1M	Sell	24,625 -583	-2%	-$20.8K	0.01%	1178
2022 Q3	$709K	Hold	25,208	–	–	0.01%	1388
2022 Q2	$680K	Hold	25,208	–	–	0.01%	1449
2022 Q1	$859K	Buy	25,208 +9,152	+57%	+$293K	0.01%	1430
2021 Q4	$620K	Hold	16,056	–	–	0.01%	1394
2021 Q3	$867K	Buy	16,056 +1,549	+11%	+$72.7K	0.01%	1194
2021 Q2	$485K	Buy	+14,507	New	+$398K	﹤0.01%	1592
2018 Q2	–	Sell	-1,561	Closed	-$55K	–	2175
2018 Q1	$55K	Sell	1,561 -2,822	-64%	-$109K	﹤0.01%	2169
2017 Q4	$187K	Buy	+4,383	New	+$188K	﹤0.01%	1960